Human umbilical cord Wharton's jelly-derived mesenchymal stem cell transplantation could improve diabetic intracavernosal pressure

Asian J Androl. 2022 Mar-Apr;24(2):171-175. doi: 10.4103/aja.aja_33_21.

Abstract

Mesenchymal stem cells (MSCs) secrete various cytokines with angiogenic and neuroprotective effects. This study aimed to assess the effects of human umbilical cord Wharton's jelly-derived MSCs (hWJ-MSCs) on diabetes-related intracavernosal pressure (ICP) impairment in rats. hWJ-MSCs were isolated from human umbilical cord Wharton's jelly and transplanted into the corpus cavernosum of streptozotocin (STZ)-induced diabetic rats by unilateral injection. The erectile function was evaluated at 4 weeks, as well as the expression levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), endothelial nitric oxide synthase (eNOS), and insulin-like growth factor 1 (IGF1). STZ-induced diabetic rats showed impaired ICP, which was significantly improved by hWJ-MSC treatment. VEGF, eNOS, IGF1, and bFGF expression levels were higher in hWJ-MSC injection sites than those in control ones in STZ-induced diabetic rats. These results suggest that hWJ-MSC transplantation might improve diabetic erectile dysfunction through increased production of paracrine growth factors, highlighting a novel potential therapeutic option for erectile dysfunction.

Keywords: diabetes; endothelial nitric oxide synthase; erectile dysfunction; mesenchymal stem cells; vascular endothelial growth factor.

MeSH terms

  • Animals
  • Cell Differentiation
  • Diabetes Mellitus, Experimental* / complications
  • Diabetes Mellitus, Experimental* / therapy
  • Erectile Dysfunction* / etiology
  • Erectile Dysfunction* / therapy
  • Humans
  • Male
  • Mesenchymal Stem Cell Transplantation* / methods
  • Rats
  • Umbilical Cord
  • Vascular Endothelial Growth Factor A
  • Wharton Jelly*

Substances

  • Vascular Endothelial Growth Factor A